---
title: "Weigao Blood Purification 2025 6.36 million restricted stock incentive plan grant results announced"
description: "Shandong Weigao Blood Purification Products Co., Ltd. announced the 2025 restricted stock incentive plan, granting 6.36 million restricted shares to 120 incentive recipients, with a grant price of 19."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259482176.md"
published_at: "2025-09-30T08:47:34.000Z"
---

# Weigao Blood Purification 2025 6.36 million restricted stock incentive plan grant results announced

> Shandong Weigao Blood Purification Products Co., Ltd. announced the 2025 restricted stock incentive plan, granting 6.36 million restricted shares to 120 incentive recipients, with a grant price of 19.77 yuan per share. The plan has a maximum validity period of 48 months, with a lock-up period starting from the registration date, and the first release of the lock-up period will be no less than 12 months. The registration is expected to be completed on September 29, raising 125.7 million yuan for liquidity support, which is expected to stimulate employee motivation and enhance long-term performance

Shandong Weigao Blood Purification Products Co., Ltd. announced the results of the 2025 restricted stock incentive plan grant. On September 16, it was determined to grant 6.36 million shares of restricted stock to 120 incentive recipients, with a grant price of 19.77 yuan per share, and the stock source is from a targeted issuance of A-share common stock. The maximum validity period is no more than 48 months, and the lock-up period starts from the date of registration, with a gap of no less than 12 months between the grant and the first release of the lock-up. Registration was completed on September 29, raising 125.7 million yuan for liquidity support. In terms of equity structure, the restricted shares increased by 6.36 million shares. The cost of this plan will be expensed, and although it will impact net profit in each year, it is expected to stimulate employee motivation and enhance long-term performance

### Related Stocks

- [22093.HK - Shandong Weigao Blood Purification Products Co., Ltd.](https://longbridge.com/en/quote/22093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SK 海力士高盛电话会：所有客户需求都无法满足，今年存储价格持续上涨 | SK 海力士在高盛电话会上释放强烈信号：存储行业已全面进入卖方市场。受 AI 真实需求驱动及洁净室空间受限影响，今年存储价格将持续上涨。公司透露目前 DRAM 及 NAND 库存仅剩约 4 周，且没有任何客户能完全满足需求。随着 2026  | [Link](https://longbridge.com/en/news/276505903.md) |
| 高瓴继续重仓中概股，HHLR 四季度增持阿里巴巴、拼多多，减持网易、百度 | 高瓴 HHLR Advisors Ltd.在四季度增持了阿里巴巴、拼多多、iShares 比特币和台积电，同时减持了网易、Bright Schol、富途控股、百度、满帮和 Webull 等。该公司重仓拼多多、阿里巴巴和富途控股。市场有风险， | [Link](https://longbridge.com/en/news/276176972.md) |
| 宇树机器人春晚武术表演再炸场，王兴兴：高动态高协同集群控制技术全球首秀 | 宇树科技创始人王兴兴表示，今年机器人的头部激光雷达、灵巧手等硬件和软件做了很多升级，“去年一整年，我们公司包括全中国的机器人的技术提升非常快，像我们公司的话，目前可以做各种的功夫动作，而且在舞台上面我们挑战了很多极限动作，可能一般的人，甚至 | [Link](https://longbridge.com/en/news/276086555.md) |
| NOW 公司｜8-K：2025 财年营收 28.2 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276438920.md) |
| AXT 公司｜8-K：2025 财年 Q4 营收 23.04 百万美元不及预期 |  | [Link](https://longbridge.com/en/news/276379119.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.